195 related articles for article (PubMed ID: 16136164)
21. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
Adhikary D; Behrends U; Moosmann A; Witter K; Bornkamm GW; Mautner J
J Exp Med; 2006 Apr; 203(4):995-1006. PubMed ID: 16549597
[TBL] [Abstract][Full Text] [Related]
22. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
23. Successful retroviral mediated transduction of a reporter gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells.
Aicher A; Westermann J; Cayeux S; Willimsky G; Daemen K; Blankenstein T; Uckert W; Dörken B; Pezzutto A
Exp Hematol; 1997 Jan; 25(1):39-44. PubMed ID: 8989905
[TBL] [Abstract][Full Text] [Related]
24. Antigen presentation by human B cells: T cell proliferation induced by Epstein Barr virus B lymphoblastoid cells.
Issekutz T; Chu E; Geha RS
J Immunol; 1982 Oct; 129(4):1446-50. PubMed ID: 6286767
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus infection negatively impacts the CXCR4-dependent migration of tonsillar B cells.
Ehlin-Henriksson B; Mowafi F; Klein G; Nilsson A
Immunology; 2006 Mar; 117(3):379-85. PubMed ID: 16476057
[TBL] [Abstract][Full Text] [Related]
26. The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo.
Westphal EM; Ge J; Catchpole JR; Ford M; Kenney SC
Cancer Gene Ther; 2000 Jan; 7(1):97-106. PubMed ID: 10678362
[TBL] [Abstract][Full Text] [Related]
27. B cells and herpesviruses: a model of lymphoproliferation.
Barozzi P; Potenza L; Riva G; Vallerini D; Quadrelli C; Bosco R; Forghieri F; Torelli G; Luppi M
Autoimmun Rev; 2007 Dec; 7(2):132-6. PubMed ID: 18035323
[TBL] [Abstract][Full Text] [Related]
28. Engineering a mini-herpesvirus as a general strategy to transduce up to 180 kb of functional self-replicating human mini-chromosomes.
Sun TQ; Livanos E; Vos JM
Gene Ther; 1996 Dec; 3(12):1081-8. PubMed ID: 8986434
[TBL] [Abstract][Full Text] [Related]
29. [Recombinant AAV-LMP-induced LMP specific cytotoxic response to autologous lymphoblastoid cell lines tranformed by Epstein-Barr virus].
Zhao F; Liu H; Zhou L; Cai W; Du B; Ye S; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):247-51. PubMed ID: 15617340
[TBL] [Abstract][Full Text] [Related]
30. An engineered EBV vector expressing human factor VIII and von Willebrand factor in cultured B-cells.
Basu U; Banerjee S
J Gene Med; 2004 Jul; 6(7):760-8. PubMed ID: 15241783
[TBL] [Abstract][Full Text] [Related]
31. A surface-modified baculovirus vector with improved gene delivery to B-lymphocytic cells.
Ge J; Huang Y; Hu X; Zhong J
J Biotechnol; 2007 May; 129(3):367-72. PubMed ID: 17374412
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
[TBL] [Abstract][Full Text] [Related]
33. Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1.
Kis LL; Takahara M; Nagy N; Klein G; Klein E
Immunol Lett; 2006 Apr; 104(1-2):83-8. PubMed ID: 16386314
[TBL] [Abstract][Full Text] [Related]
34. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of nasopharyngeal carcinoma growth by RTA-expressing baculovirus vectors containing oriP.
Wang L; Shan L; Lo KW; Yin J; Zhang Y; Sun R; Zhong J
J Gene Med; 2008 Oct; 10(10):1124-33. PubMed ID: 18642396
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-13 gene expression by malignant and EBV-transformed human B lymphocytes.
Fior R; Vita N; Raphael M; Minty A; Maillot MC; Crevon MC; Caput D; Biberfeld P; Ferrara P; Galanaud P
Eur Cytokine Netw; 1994; 5(6):593-600. PubMed ID: 7727691
[TBL] [Abstract][Full Text] [Related]
37. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.
Janke M; Peeters B; de Leeuw O; Moorman R; Arnold A; Fournier P; Schirrmacher V
Gene Ther; 2007 Dec; 14(23):1639-49. PubMed ID: 17914407
[TBL] [Abstract][Full Text] [Related]
38. The activation of lytic replication of Epstein-Barr virus by baculovirus-mediated gene transduction.
Wang L; Shan L; Yin J; Zhao M; Su D; Zhong J
Arch Virol; 2006 Oct; 151(10):2047-53. PubMed ID: 16673043
[TBL] [Abstract][Full Text] [Related]
39. Viral vectors for gene transfer into antigen presenting cells.
Monahan SJ; Salgaller ML
Curr Opin Mol Ther; 1999 Oct; 1(5):558-64. PubMed ID: 11249662
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus: exploiting the immune system.
Thorley-Lawson DA
Nat Rev Immunol; 2001 Oct; 1(1):75-82. PubMed ID: 11905817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
